Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Senzime AB (publ)    SEZI   SE0002478776

SENZIME AB (PUBL)

(SEZI)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Eva Walde strengthens Senzime's Board of Directors

10/19/2020 | 02:46am EST

Press release: Uppsala, October 19, 2020. Senzime announces that Eva Walde is appointed new acting Board Member to be elected at the next shareholder's meeting.

[image]  

Eva has a Master's degree in economics from the Gothenburg School of Economics and over 20 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher. Eva is currently a Board member of Sedana Medical AB (publ.), a volatile anaesthetic delivery company, and the VP of Marketing at Olink AB."We are very pleased to appoint such an experienced person as Eva Walde to Senzime's Board. Eva has solid background in international sales and marketing of medical technology and will be a great asset for Senzime in the commercial phase we are in now," says Philip Siberg, Chairman of the Board of Senzime.

The appointment of a new Board member has taken place through an external recruitment process on behalf of the Nomination Committee of Senzime, consisting of Philip Siberg, Adam Dahlberg, Lennart Kalén and Sorin J. Brull.

For further information, please contact:

Philip Siberg, Chairman of the Board

Tel: +46 70 790 67 34

Pia Renaudin, CEO          

Phone: +46 70-813 34 17, e-post: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses - before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs - in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se,  is Certified Adviser for Senzime. www.senzime.com  

https://news.cision.com/senzime/r/eva-walde-strengthens-senzime-s-board-of-directors,c3217902

https://mb.cision.com/Main/11572/3217902/1320446.pdf

https://news.cision.com/senzime/i/bild-eva-walde-pm-201019,c2839484

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.58% 149 Delayed Quote.2.15%
SENZIME AB (PUBL) -3.95% 21.9 End-of-day quote.20.33%
THERMO FISHER SCIENTIFIC -0.35% 477.2 Delayed Quote.47.41%
All news about SENZIME AB (PUBL)
12/02SENZIME : has carried out a directed issue of 4,545,000 shares, raising proceeds..
AQ
12/02SENZIME : announces intention to carry out a directed issue of approximately SEK..
AQ
11/26SENZIME : announces outcome in employee stock option program, issues 600 000 sha..
PU
11/26SENZIME : announces outcome in employee stock option program, issues 600 000 sha..
AQ
11/25SENZIME : lands a new order from South Korea on systems and disposable sensors t..
AQ
11/13VATOR SECURITIES : Closing the valuation gap driven by 90% likelihood of achievi..
AQ
11/06SENZIME : Interim report January - September 2020
AQ
11/04SENZIME : Nomination Committee in Senzime ahead of the 2021 Annual General Meeti..
AQ
11/02SENZIME : out-licenses OnZurf Probe on the European market
PU
11/02SENZIME : out-licenses OnZurf Probe on the European market
AQ
More news
Financials
Sales 2019 6,71 M 0,79 M 0,79 M
Net income 2019 -33,7 M -3,99 M -3,99 M
Net cash 2019 30,9 M 3,66 M 3,66 M
P/E ratio 2019 -26,7x
Yield 2019 -
Capitalization 1 369 M 162 M 162 M
EV / Sales 2018 104x
EV / Sales 2019 138x
Nbr of Employees -
Free-Float 70,3%
Chart SENZIME AB (PUBL)
Duration : Period :
Senzime AB (publ) Technical Analysis Chart | SEZI | SE0002478776 | MarketScreener
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 21,90 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Pia Renaudin Chief Executive Officer
Philip Axel Wilhelm Siberg Chairman
Erik Bergman Chief Financial Officer
David Robert Hampton Chief Scientific Officer
Anders Jacobson Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SENZIME AB (PUBL)20.33%162
ABBOTT LABORATORIES23.80%191 681
MEDTRONIC PLC-0.86%152 346
BECTON, DICKINSON AND COMPANY-12.30%70 150
HOYA CORPORATION24.59%48 552
ALIGN TECHNOLOGY, INC.83.39%39 857